| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:211.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
From the Division of Clinical Pharmacology, Department of Medicine (R.A.P., G.A.), and Wallace H. Coulter Platelet Laboratory, Department of Medicine (W.J., J.J.J., L.M.M., L.L.H., M.V., Y.S.A.), University of Miami School of Medicine, Miami, Fla.
Correspondence to Richard A Preston, MD, Division of Clinical Pharmacology, 1500 NW 12th Ave, 15th Floor, West Tower, Miami, FL 33136. E-mail rpreston{at}med.miami.edu
The molecular mechanisms by which extreme blood pressure elevation leads to vascular injury are not defined. To explore the hypothesis that activation of endothelium and platelets as manifested by increased concentrations of circulating endothelial microparticles and platelet microparticles could play a role in this target organ injury, we conducted a cross-sectional study of these markers in 3 groups: (1) untreated patients referred specifically for treatment of severe uncontrolled hypertension; (2) untreated patients with established mild hypertension; and (3) normotensive volunteer subjects. By ANOVA, endothelial (P=0.002) and platelet (P=0.01) microparticles were greatest in the severely hypertensive group. There was a significant correlation between both of these markers and blood pressure, even in the setting of multiple risk factors. Our results suggest that these markers may be useful and specific for pressure-induced endothelial and platelet activation in hypertension. Furthermore, because of the combined effects of endothelial and platelet microparticles on coagulation, leukocytes, and endothelium, it is possible that they may play a pathogenic role in mediating target organ injury in severe hypertension.
Key Words: hypertension, arterial endothelium platelets endothelium-derived factors cell adhesion molecules
This article has been cited by other articles:
![]() |
I. Dursun, H. M Poyrazoglu, Z. Gunduz, H. Ulger, A. Yykylmaz, R. Dusunsel, T. Patyroglu, and M. Gurgoze The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease Nephrol. Dial. Transplant., August 1, 2009; 24(8): 2511 - 2518. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Pericleous, I Giles, and A Rahman Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome? Lupus, July 1, 2009; 18(8): 671 - 675. [Abstract] [PDF] |
||||
![]() |
L. Ayers, B. Ferry, S. Craig, D. Nicoll, J. R. Stradling, and M. Kohler Circulating cell-derived microparticles in patients with minimally symptomatic obstructive sleep apnoea Eur. Respir. J., March 1, 2009; 33(3): 574 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Choudhury, I. Chung, A. D. Blann, and G. Y. H. Lip Elevated Platelet Microparticle Levels in Nonvalvular Atrial Fibrillation: Relationship to P-Selectin and Antithrombotic Therapy Chest, March 1, 2007; 131(3): 809 - 815. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Morel, F. Toti, B. Hugel, B. Bakouboula, L. Camoin-Jau, F. Dignat-George, and J.-M. Freyssinet Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation? Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2594 - 2604. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wassmann, N. Werner, T. Czech, and G. Nickenig Improvement of Endothelial Function by Systemic Transfusion of Vascular Progenitor Cells Circ. Res., October 13, 2006; 99(8): E74 - E83. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Boulanger, N. Amabile, and A. Tedgui Circulating Microparticles: A Potential Prognostic Marker for Atherosclerotic Vascular Disease Hypertension, August 1, 2006; 48(2): 180 - 186. [Full Text] [PDF] |
||||
![]() |
H. Koga, S. Sugiyama, K. Kugiyama, H. Fukushima, K. Watanabe, T. Sakamoto, M. Yoshimura, H. Jinnouchi, and H. Ogawa Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease Eur. Heart J., April 1, 2006; 27(7): 817 - 823. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Werner and G. Nickenig Influence of Cardiovascular Risk Factors on Endothelial Progenitor Cells: Limitations for Therapy? Arterioscler Thromb Vasc Biol, February 1, 2006; 26(2): 257 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Werner, S. Wassmann, P. Ahlers, S. Kosiol, and G. Nickenig Circulating CD31+/Annexin V+ Apoptotic Microparticles Correlate With Coronary Endothelial Function in Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 112 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Amabile, A. P. Guerin, A. Leroyer, Z. Mallat, C. Nguyen, J. Boddaert, G. M. London, A. Tedgui, and C. M. Boulanger Circulating Endothelial Microparticles Are Associated with Vascular Dysfunction in Patients with End-Stage Renal Failure J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3381 - 3388. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mezentsev, R. M. H. Merks, E. O'Riordan, J. Chen, N. Mendelev, M. S. Goligorsky, and S. V. Brodsky Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1106 - H1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Koga, S. Sugiyama, K. Kugiyama, K. Watanabe, H. Fukushima, T. Tanaka, T. Sakamoto, M. Yoshimura, H. Jinnouchi, and H. Ogawa Elevated Levels of VE-Cadherin-Positive Endothelial Microparticles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1622 - 1630. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Swampillai, S. Doshi, A. G Fraser, J. Goodfellow, and C. J. Jones Review: Clinical assessment of endothelial function -- an update The British Journal of Diabetes & Vascular Disease, March 1, 2005; 5(2): 72 - 76. [Abstract] [PDF] |
||||
![]() |
M. C. Martinez, A. Tesse, F. Zobairi, and R. Andriantsitohaina Shed membrane microparticles from circulating and vascular cells in regulating vascular function Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1004 - H1009. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Ferreira, A. A. Peter, A. J. Mendez, J. J. Jimenez, L. M. Mauro, J. A. Chirinos, R. Ghany, S. Virani, S. Garcia, L. L. Horstman, et al. Postprandial Hypertriglyceridemia Increases Circulating Levels of Endothelial Cell Microparticles Circulation, December 7, 2004; 110(23): 3599 - 3603. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kimura, X. Lu, J. Skurnick, G. Awad, J. Bogden, F. Kemp, and A. Aviv Potassium Chloride Supplementation Diminishes Platelet Reactivity in Humans Hypertension, December 1, 2004; 44(6): 969 - 973. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Brodsky, F. Zhang, A. Nasjletti, and M. S. Goligorsky Endothelium-derived microparticles impair endothelial function in vitro Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1910 - H1915. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T Keller, A. T.A Mairuhu, M. D de Kruif, S. K Klein, V. E.A Gerdes, H. ten Cate, D. P.M Brandjes, M. Levi, and E. C.M van Gorp Infections and endothelial cells Cardiovasc Res, October 15, 2003; 60(1): 40 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Blann, S. Nadar, and G. Y.H. Lip Pharmacological Modulation of Platelet Function in Hypertension Hypertension, July 1, 2003; 42(1): 1 - 7. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Y.H. Lip Hypertension, Platelets, and the Endothelium: The "Thrombotic Paradox" of Hypertension (or "Birmingham Paradox") Revisited Hypertension, February 1, 2003; 41(2): 199 - 200. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |